On the public citation graph
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
0 signed · 1651 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1016/j.ccr.2005.01.007openalex-snapshot
Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl
inferredcites →https://doi.org/10.1038/leu.2009.166openalex-snapshot
Nilotinib concentration in cell lines and primary CD34+ chronic myeloid leukemia cells is not mediated by active uptake or efflux by major drug transporters
inferredcites →https://doi.org/10.1038/leu.2009.168openalex-snapshot
Harmonization of molecular monitoring of CML therapy in Europe
inferredcites →https://doi.org/10.1038/leu.2009.38openalex-snapshot
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
inferredcites →https://doi.org/10.1038/sj.leu.2404388openalex-snapshot
Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia
inferredcites →https://doi.org/10.1038/sj.leu.2404983openalex-snapshot
Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories
inferredcites →https://doi.org/10.1056/nejmoa022457openalex-snapshot
Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa030513openalex-snapshot
Frequency of Major Molecular Responses to Imatinib or Interferon Alfa plus Cytarabine in Newly Diagnosed Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa062867openalex-snapshot
Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia
inferredcites →https://doi.org/10.1097/00000421-198212000-00014openalex-snapshot
Toxicity and response criteria of the Eastern Cooperative Oncology Group
inferredcites →https://doi.org/10.1158/1078-0432.ccr-04-2139openalex-snapshot
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
inferredcites →https://doi.org/10.1182/blood-2006-01-0092openalex-snapshot
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
inferredcites →https://doi.org/10.1182/blood-2006-02-005686openalex-snapshot
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
inferredcites →https://doi.org/10.1182/blood-2008-04-150680openalex-snapshot
Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials
inferredcites →https://doi.org/10.1182/blood-2008-05-158535openalex-snapshot
15-deoxy-Δ12,14-PGJ2 enhances platelet production from megakaryocytes
inferredcites →https://doi.org/10.1182/blood-2009-03-210039openalex-snapshot
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
inferredcites →https://doi.org/10.1182/blood-2009-07-232595openalex-snapshot
Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia
inferredcites →https://doi.org/10.1182/blood.v110.11.29.29openalex-snapshot
Efficacy of Nilotinib (AMN107) in Patients (Pts) with Newly Diagnosed, Previously Untreated Philadelphia Chromosome (Ph)-Positive Chronic Myelogenous Leukemia in Early Chronic Phase (CML-CP).
inferredcites →https://doi.org/10.1182/blood.v114.22.1126.1126openalex-snapshot
International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.
inferredcites →https://doi.org/10.1182/blood.v114.22.142.142openalex-snapshot
The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL.
inferredcites →https://doi.org/10.1182/blood.v114.22.143.143openalex-snapshot
Developmentally Restricted Protection From Notch1-Induced T Cell Acute Lymphoblastic Leukemia by the Arf Tumor Suppressor.
inferredcites →https://doi.org/10.1182/blood.v114.22.2205.2205openalex-snapshot
Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.
inferredcites →https://doi.org/10.1182/blood.v114.22.337.337openalex-snapshot
24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).
inferredcites →https://doi.org/10.1182/blood.v114.22.339.339openalex-snapshot
Randomized Comparison of Imatinib 800 Mg Vs. Imatinib 400 Mg +/- IFN in Newly Diagnosed BCR/ABL Positive Chronic Phase CML: Analysis of Molecular Remission at 12 Months; The German CML-Study IV.
inferredcites →https://doi.org/10.1182/blood.v114.22.462.462openalex-snapshot
Unstable Alpha Hemoglobin Stabilizing Protein as a Cause of Thalassemia: Proof of Concept.
inferredcites →https://doi.org/10.1182/blood.v63.4.789.bloodjournal634789openalex-snapshot
Prognostic discrimination in "good-risk" chronic granulocytic leukemia
inferredcites →https://doi.org/10.1200/jco.2009.25.0779openalex-snapshot
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
inferredcites →https://doi.org/10.1200/jco.2009.25.3724openalex-snapshot
Phase III, Randomized, Open-Label Study of Daily Imatinib Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study
inferredcites →https://doi.org/10.1200/jco.2009.25.4896openalex-snapshot
Nilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.3897/pharmacia.71.e126016zenodo-depositor-declared
Analysis of the pharmacoeconomic effectiveness of the tyrosine kinase inhibitors therapy in patients with chronic myeloid leukemia in a Single Hematology Center in Plovdiv, Bulgaria
inferred← citeshttps://doi.org/10.3897/pharmacia.73.e190815zenodo-depositor-declared
Oncopharmacological aspects of Bcr-Abl inhibitors: from revolutionary structure-based design to clinical resistance
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2021.20165openalex-snapshot
Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1001/jamaoncol.2015.5932openalex-snapshot
Association Between BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia and Cardiovascular Events, Major Molecular Response, and Overall Survival
inferred← citeshttps://doi.org/10.1001/jamaoncol.2017.0580openalex-snapshot
Association of Minimal Residual Disease With Clinical Outcome in Pediatric and Adult Acute Lymphoblastic Leukemia
inferred← citeshttps://doi.org/10.1001/jamaoncol.2020.4660openalex-snapshot
Association of Generic Imatinib Availability and Pricing With Trends in Tyrosine Kinase Inhibitor Use in Patients With Chronic Myelogenous Leukemia
inferred← citeshttps://doi.org/10.1002/3527600906.mcb.201500002openalex-snapshot
Cancer Pharmacogenomics
inferred← citeshttps://doi.org/10.1002/9780470015902.a0002181.pub2openalex-snapshot
Chronic Myeloid Leukaemia
inferred← citeshttps://doi.org/10.1002/9781118098141.ch20openalex-snapshot
Drug Research Leading to Imatinib and beyond to Nilotinib
inferred← citeshttps://doi.org/10.1002/9781118219683.ch5openalex-snapshot
Setting the Paradigm of Targeted Drugs for the Treatment of Cancer: Imatinib and Nilotinib, Therapies for Chronic Myelogenous Leukemia
inferred← citeshttps://doi.org/10.1002/9781118416426.ch25openalex-snapshot
The Detection and Significance of Minimal Residual Disease
inferred← citeshttps://doi.org/10.1002/9781118416426.ch48openalex-snapshot
Hematopoietic Stem Cell Transplantation for Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1002/9781118464557.ch47openalex-snapshot
Myeloproliferative Neoplasms: Chronic Myelogenous Leukemia, Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis
inferred← citeshttps://doi.org/10.1002/9781118468678.ch11openalex-snapshot
Targeted Therapies in Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1002/9781118527948.ch7openalex-snapshot
The genetics of chronic myelogenous leukaemia
inferred← citeshttps://doi.org/10.1002/9781118589199.ch21openalex-snapshot
Chronic Myeloid Leukemia: Chronic Phase
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm116openalex-snapshot
Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1002/9781119196235.ch55openalex-snapshot
Myeloproliferative Neoplasms
inferred← citeshttps://doi.org/10.1002/9781119196235.ch81openalex-snapshot
Rare Hematological Malignancies in Children
inferred← citeshttps://doi.org/10.1002/9781444345254.ch18openalex-snapshot
Myeloproliferative Neoplasms and Myelodysplastic Syndromes
inferred← citeshttps://doi.org/10.1002/9783527677252.ch02openalex-snapshot
Discovery of Predictive Biomarkers for Anticancer Drugs
inferred← citeshttps://doi.org/10.1002/acg2.85openalex-snapshot
When to consider allogeneic transplant for chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/ajh.21999openalex-snapshot
ASH 2010 meeting report—Top 10 clinically oriented abstracts in chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/ajh.22037openalex-snapshot
Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML
inferred← citeshttps://doi.org/10.1002/ajh.22051openalex-snapshot
Nilotinib treatment‐associated peripheral artery disease and sudden death: Yet another reason to stick to imatinib as front‐line therapy for chronic myelogenous leukemia
inferred← citeshttps://doi.org/10.1002/ajh.22076openalex-snapshot
High‐dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients—Systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/ajh.22084openalex-snapshot
Choosing the right TKI for chronic myeloid leukemia: When the truth lies in “long‐term” safety and efficacy
inferred← citeshttps://doi.org/10.1002/ajh.22097openalex-snapshot
Chronic myeloid leukemia 2011: Successes, challenges, and strategies—Proceedings of the 5th annual BCR‐ABL1 positive and BCR‐ABL1 negative myeloproliferative neoplasms workshop
inferred← citeshttps://doi.org/10.1002/ajh.22272openalex-snapshot
BCR‐ABL1 kinase domain mutations: Methodology and clinical evaluation
inferred← citeshttps://doi.org/10.1002/ajh.23125openalex-snapshot
Pharmacokinetics of nilotinib in imatinib‐resistant/intolerant chronic myeloid leukemia patients on hemodialysis for chronic renal failure
inferred← citeshttps://doi.org/10.1002/ajh.23238openalex-snapshot
Early landmark analysis of imatinib treatment in CML chronic phase: Less than 10% BCR‐ABL by FISH at 3 months associated with improved long‐term clinical outcome
inferred← citeshttps://doi.org/10.1002/ajh.23282openalex-snapshot
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
inferred← citeshttps://doi.org/10.1002/ajh.23321openalex-snapshot
The differences and correlations of BCR‐ABL transcripts between peripheral blood and bone marrow assays are associated with the molecular responses in the bone marrow for chronic myelogenous leukemia
inferred← citeshttps://doi.org/10.1002/ajh.23330openalex-snapshot
Long‐term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia: Results of the AFR04 study
inferred← citeshttps://doi.org/10.1002/ajh.23338openalex-snapshot
Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1002/ajh.23442openalex-snapshot
Nilotinib treatment‐associated cerebrovascular disease and stroke
inferred← citeshttps://doi.org/10.1002/ajh.23560openalex-snapshot
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1002/ajh.23626openalex-snapshot
Involvement of primary mesenchymal precursors and hematopoietic bone marrow cells from chronic myeloid leukemia patients by BCR‐ABL1 fusion gene
inferred← citeshttps://doi.org/10.1002/ajh.23691openalex-snapshot
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
inferred← citeshttps://doi.org/10.1002/ajh.23776openalex-snapshot
Inhibition of calcineurin combined with dasatinib has direct and indirect anti‐leukemia effects against BCR‐ABL1+ leukemia
inferred← citeshttps://doi.org/10.1002/ajh.23804openalex-snapshot
First‐line treatment of 102 chronic myeloid leukemia patients with imatinib: A long‐term single institution analysis
inferred← citeshttps://doi.org/10.1002/ajh.23864openalex-snapshot
ELN 2013 response status criteria: Relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?
inferred← citeshttps://doi.org/10.1002/ajh.23887openalex-snapshot
How I treat newly diagnosed chronic myeloid leukemia in 2015
inferred← citeshttps://doi.org/10.1002/ajh.23902openalex-snapshot
Molecular monitoring to improve outcomes in patients with chronic myeloid leukemia in chronic phase: Importance of achieving treatment‐free remission
inferred← citeshttps://doi.org/10.1002/ajh.23923openalex-snapshot
Shorter halving time of BCR‐ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic‐phase chronic myeloid leukemia treated with dasatinib: Results of the D‐first study of K anto CML study group
inferred← citeshttps://doi.org/10.1002/ajh.23973openalex-snapshot
Bosutinib shows low cross intolerance, in chronic myeloid leukemia patients treated in fourth line. Results of the S panish compassionate use program
inferred← citeshttps://doi.org/10.1002/ajh.24137openalex-snapshot
Long‐term follow‐up of imatinib plus combination chemotherapy in patients with newly diagnosed P hiladelphia chromosome‐positive acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1002/ajh.24247openalex-snapshot
Chronic myeloid leukemia: Second‐line drugs of choice
inferred← citeshttps://doi.org/10.1002/ajh.24249openalex-snapshot
Chronic myeloid leukemia: First‐line drug of choice
inferred← citeshttps://doi.org/10.1002/ajh.24275openalex-snapshot
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
inferred← citeshttps://doi.org/10.1002/ajh.24362openalex-snapshot
Rotation of nilotinib and imatinib for first‐line treatment of chronic phase chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/ajh.24381openalex-snapshot
Monitoring disease burden in chronic myeloid leukemia: Past, present, and future
inferred← citeshttps://doi.org/10.1002/ajh.24591openalex-snapshot
A population‐based study of chronic myeloid leukemia patients treated with imatinib in first line
inferred← citeshttps://doi.org/10.1002/ajh.24774openalex-snapshot
The BCR‐ABL1 transcript type influences response and outcome in P hiladelphia chromosome‐positive chronic myeloid leukemia patients treated frontline with imatinib
inferred← citeshttps://doi.org/10.1002/ajh.24793openalex-snapshot
Clinical impact of pretransplant use of multiple tyrosine kinase inhibitors on the outcome of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia
inferred← citeshttps://doi.org/10.1002/ajh.24887openalex-snapshot
First‐line treatment selection and early monitoring patterns in chronic phase‐chronic myeloid leukemia in routine clinical practice: SIMPLICITY
inferred← citeshttps://doi.org/10.1002/ajh.25011openalex-snapshot
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
inferred← citeshttps://doi.org/10.1002/ajh.25306openalex-snapshot
Tyrosine kinase inhibitor interruptions, discontinuations and switching in patients with chronic‐phase chronic myeloid leukemia in routine clinical practice: SIMPLICITY
inferred← citeshttps://doi.org/10.1002/ajh.25792openalex-snapshot
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
inferred← citeshttps://doi.org/10.1002/ajh.26463openalex-snapshot
Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow‐up of patients diagnosed 2002–2017 in a complete coverage and nationwide agnostic register study
inferred← citeshttps://doi.org/10.1002/ajh.26556openalex-snapshot
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success
inferred← citeshttps://doi.org/10.1002/ajh.26642openalex-snapshot
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring
inferred← citeshttps://doi.org/10.1002/ajh.26764openalex-snapshot
Allogeneic hematopoietic cell transplantation in patients with chronic phase chronic myeloid leukemia in the era of third generation tyrosine kinase inhibitors: A retrospective study by the chronic malignancies working party of the EBMT
inferred← citeshttps://doi.org/10.1002/ajh.27037openalex-snapshot
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation treated in the pre‐ and post‐ponatinib era
inferred← citeshttps://doi.org/10.1002/ajh.27443openalex-snapshot
Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring
inferred← citeshttps://doi.org/10.1002/ana.25947openalex-snapshot
Cardiovascular Safety of Nilotinib in Alzheimer Disease
inferred← citeshttps://doi.org/10.1002/ange.201802416openalex-snapshot
Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen
inferred← citeshttps://doi.org/10.1002/anie.201802416openalex-snapshot
A Structural View on Medicinal Chemistry Strategies against Drug Resistance
inferred← citeshttps://doi.org/10.1002/cam4.1450openalex-snapshot
A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome‐positive chronic myeloid leukemia in chronic phase: ENESTK orea
inferred← citeshttps://doi.org/10.1002/cam4.1808openalex-snapshot
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second‐ and third‐generation tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1002/cam4.3034openalex-snapshot
Optimal treatment strategy with nilotinib for patients with newly diagnosed chronic‐phase chronic myeloid leukemia based on early achievement of deep molecular response (MR4.5): The phase 2, multicenter N‐Road study
inferred← citeshttps://doi.org/10.1002/cbin.70007openalex-snapshot
Different In Vitro Models of Chronic Myeloid Leukemia Show Different Characteristics: Biological Replicates Are Not Biologically Equivalent
inferred← citeshttps://doi.org/10.1002/ccr3.1253openalex-snapshot
Tyrosine kinase inhibitor and rituximab‐ CHOP treatment for concurrent chronic myeloid leukemia and non‐Hodgkin lymphoma: a case report
inferred← citeshttps://doi.org/10.1002/ccr3.2191openalex-snapshot
Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
inferred← citeshttps://doi.org/10.1002/ccr3.4357openalex-snapshot
Successful determination of imatinib re‐administration dosage by therapeutic drug monitoring in a case of chronic myeloid leukemia initiating dialysis for acute renal dysfunction
inferred← citeshttps://doi.org/10.1002/ccr3.5openalex-snapshot
Reversible ventricular arrythmia induced by dasatinib
inferred← citeshttps://doi.org/10.1002/ccr3.506openalex-snapshot
Transient monosomy 7 in a chronic myelogenous leukemia patient during nilotinib therapy: a case report
inferred← citeshttps://doi.org/10.1002/ccr3.729openalex-snapshot
Extensive intracranial arterial stenoses in conjunction with the use of tyrosine kinase inhibitor Nilotinib
inferred← citeshttps://doi.org/10.1002/cmdc.201700829openalex-snapshot
Alkynylnicotinamide‐Based Compounds as ABL1 Inhibitors with Potent Activities against Drug‐Resistant CML Harboring ABL1(T315I) Mutant Kinase
inferred← citeshttps://doi.org/10.1002/cmdc.70502openalex-snapshot
Synthesis, Biological Evaluation, and Molecular Modeling of Novel Pyrimidine Scaffolds as Prospective Anticancer and Antimicrobial Agents
inferred← citeshttps://doi.org/10.1002/cncr.25600openalex-snapshot
Second‐generation tyrosine kinase inhibitors in chronic myelogenous leukemia
inferred← citeshttps://doi.org/10.1002/cncr.25648openalex-snapshot
Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.25717openalex-snapshot
Practical advice for determining the role of BCR‐ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.26062openalex-snapshot
Practical management of patients with chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.26196openalex-snapshot
Early cytogenetic and molecular response during first‐line treatment of chronic myeloid leukemia in chronic phase
inferred← citeshttps://doi.org/10.1002/cncr.26280openalex-snapshot
Measuring response to BCR‐ABL inhibitors in chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.26391openalex-snapshot
Suboptimal responses in chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.26679openalex-snapshot
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
inferred← citeshttps://doi.org/10.1002/cncr.27506openalex-snapshot
Evaluation of residual CD34+Ph+ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first‐line nilotinib therapy
inferred← citeshttps://doi.org/10.1002/cncr.29141openalex-snapshot
Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or P hiladelphia chromosome–positive acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1002/cncr.29142openalex-snapshot
Predicting early blast transformation in chronic‐phase chronic myeloid leukemia: Is immunophenotyping the missing link?
inferred← citeshttps://doi.org/10.1002/cncr.29240openalex-snapshot
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic‐ or accelerated‐phase chronic myeloid leukemia: Results with 24 months of follow‐up
inferred← citeshttps://doi.org/10.1002/cncr.29383openalex-snapshot
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1002/cncr.30197openalex-snapshot
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
inferred← citeshttps://doi.org/10.1002/cncr.31133openalex-snapshot
Validity and usefulness of a single‐item measure of patient‐reported bother from side effects of cancer therapy
inferred← citeshttps://doi.org/10.1002/cncr.31323openalex-snapshot
Health‐related quality of life in patients with chronic myeloid leukemia receiving first‐line therapy with nilotinib
inferred← citeshttps://doi.org/10.1002/cncr.31357openalex-snapshot
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic‐phase chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.31835openalex-snapshot
Molecular monitoring of therapeutic milestones and clinical outcomes in patients with chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.32443openalex-snapshot
Late mortality after bone marrow transplant for chronic myelogenous leukemia in the context of prior tyrosine kinase inhibitor exposure: A Blood or Marrow Transplant Survivor Study (BMTSS) report
inferred← citeshttps://doi.org/10.1002/cncr.32504openalex-snapshot
Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.32623openalex-snapshot
Long‐term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic‐phase chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.35317openalex-snapshot
Combination of dasatinib and venetoclax in newly diagnosed chronic phase chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/cncr.35384openalex-snapshot
Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase
inferred← citeshttps://doi.org/10.1002/cncr.35953openalex-snapshot
Management of chronic myeloid leukemia in 2025
inferred← citeshttps://doi.org/10.1002/cncr.70524openalex-snapshot
Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR‐ABL1 transcript decline velocity in chronic myeloid leukemia: A 16‐year real‐world study
inferred← citeshttps://doi.org/10.1002/hec.3899openalex-snapshot
Do cancer treatments have option value? Real‐world evidence from metastatic melanoma
inferred← citeshttps://doi.org/10.1002/hon.2274openalex-snapshot
Impact of exclusion criteria for the DASISION and ENESTnd trials in the front‐line treatment of a ‘real‐life’ patient population with chronic myeloid leukaemia
inferred← citeshttps://doi.org/10.1002/hon.3000openalex-snapshot
The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation
inferred← citeshttps://doi.org/10.1002/hon.3040openalex-snapshot
BCR/ABL1ΔE7‐8‐9 isoform contributes to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1002/ijc.29889openalex-snapshot
Tyrosine kinase inhibitors as a first‐line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed‐treatment comparison
inferred← citeshttps://doi.org/10.1002/jcb.26686openalex-snapshot
Effects of antioxidants on apoptosis induced by dasatinib and nilotinib in K562 cells
inferred← citeshttps://doi.org/10.1002/jcla.22612openalex-snapshot
Development and evaluation of armored RNA ‐based standards for quantification of BCR ‐ ABL 1p210/p190 fusion gene transcripts
inferred← citeshttps://doi.org/10.1002/jcla.24598openalex-snapshot
Simultaneous quantification of dasatinib, nilotinib, bosutinib, and ponatinib using high‐performance liquid chromatography–Photodiode array detection
inferred← citeshttps://doi.org/10.1002/jcp.31417openalex-snapshot
Cancer knocks you out by fasting: Cachexia as a consequence of metabolic alterations in cancer
inferred← citeshttps://doi.org/10.1002/jha2.21openalex-snapshot
Delayed acute pancreatitis induced by nilotinib in a patient with chronic myeloid leukemia attaining sustained complete molecular response
inferred← citeshttps://doi.org/10.1002/jha2.685openalex-snapshot
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study
inferred← citeshttps://doi.org/10.1002/mco2.181openalex-snapshot
Small molecule inhibitors targeting the cancers
inferred← citeshttps://doi.org/10.1002/mds.28733openalex-snapshot
Cardiovascular Safety of Nilotinib in Parkinson's Disease
inferred← citeshttps://doi.org/10.1002/msj.20225openalex-snapshot
Myeloproliferative Neoplasms: New Translational Therapies
inferred← citeshttps://doi.org/10.1002/onco.13944openalex-snapshot
Tyrosine Kinase Inhibitors and Vascular Adverse Events in Patients with Chronic Myeloid Leukemia: A Population-Based , Propensity Score-Matched Cohort Study
inferred← citeshttps://doi.org/10.1002/pbc.22484openalex-snapshot
Imatinib mesylate in children and adolescents with cancer
inferred← citeshttps://doi.org/10.1002/pbc.30059openalex-snapshot
Cardiovascular toxicities with pediatric tyrosine kinase inhibitor therapy: An analysis of adverse events reported to the Food and Drug Administration
inferred← citeshttps://doi.org/10.1002/phar.1266openalex-snapshot
Treatment‐, Patient‐, and Disease‐Related Factors and the Emergence of Adverse Events with Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1002/phar.1893openalex-snapshot
Evaluation of Long‐Term Chronic Myeloid Leukemia Treatment Practices with Tyrosine Kinase Inhibitors in a National Cohort of Veterans
inferred← citeshttps://doi.org/10.1002/pmic.201200022openalex-snapshot
Quantitative proteomics analysis of BMS ‐214662 effects on CD 34 positive cells from chronic myeloid leukaemia patients
inferred← citeshttps://doi.org/10.1002/prp2.1005openalex-snapshot
Real‐world efficacy and safety outcomes of imatinib treatment in patients with chronic myeloid leukemia: An Australian experience
inferred← citeshttps://doi.org/10.1002/rcr2.70717openalex-snapshot
Chronic Myeloid Leukaemia Developing During Long‐Term Alectinib Therapy Successfully Managed With Concomitant Nilotinib: A Case Report
inferred← citeshttps://doi.org/10.1002/vrc2.70071openalex-snapshot
Toceranib phosphate‐associated diabetes mellitus in a dog
inferred← citeshttps://doi.org/10.1007/164_2017_81openalex-snapshot
Mechanisms of Resistance to Targeted Therapies in Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-1-4614-3764-2_5openalex-snapshot
Diagnosis and Treatment of Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-1-4614-3828-1_9openalex-snapshot
Therapeutic Drug Monitoring of Targeted Anticancer Therapy. Tyrosine Kinase Inhibitors and Selective Estrogen Receptor Modulators: A Clinical Pharmacology Laboratory Perspective
inferred← citeshttps://doi.org/10.1007/978-1-4614-9135-4_38openalex-snapshot
The Role of Phase III Trials in Modern Drug Development
inferred← citeshttps://doi.org/10.1007/978-1-59745-458-2_43openalex-snapshot
Personalized Medicine for the Treatment of Human Cancer
inferred← citeshttps://doi.org/10.1007/978-1-60761-565-1_4openalex-snapshot
Chronic Myeloid Leukemia (CML)
inferred← citeshttps://doi.org/10.1007/978-1-60761-565-1_9openalex-snapshot
The Detection and Significance of Minimal Residual Disease
inferred← citeshttps://doi.org/10.1007/978-1-61779-407-0_4openalex-snapshot
KIT as a Therapeutic Target for Melanoma
inferred← citeshttps://doi.org/10.1007/978-3-030-71913-5_10openalex-snapshot
A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-3-030-71913-5_11openalex-snapshot
The Role of Hematopoietic Stem Cell Transplantation in CML
inferred← citeshttps://doi.org/10.1007/978-3-030-71913-5_5openalex-snapshot
CML Therapy: A Focus on Second- and Third-Generation Tyrosine Kinase Inhibitors
inferred← citeshttps://doi.org/10.1007/978-3-030-71913-5_6openalex-snapshot
Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-3-030-71913-5_9openalex-snapshot
Prognostic Scores for Patients with Chronic Myeloid Leukemia under Particular Consideration of Disease-Specific Death
inferred← citeshttps://doi.org/10.1007/978-3-319-08350-6_4openalex-snapshot
Management of Patients with Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-3-319-30273-7_3openalex-snapshot
Cytokine Receptors and Signaling
inferred← citeshttps://doi.org/10.1007/978-3-319-33198-0_15openalex-snapshot
Changing the Cost of Care for Chronic Myeloid Leukemia: The Availability of Generic Imatinib in the USA and the EU
inferred← citeshttps://doi.org/10.1007/978-3-319-33198-0_3openalex-snapshot
The Choice of First-Line Chronic Myelogenous Leukemia Treatment
inferred← citeshttps://doi.org/10.1007/978-3-319-33198-0_4openalex-snapshot
A Review and an Update of European LeukemiaNet Recommendations for the Management of Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-3-319-33198-0_5openalex-snapshot
Management of Adverse Events Associated with ATP-Competitive BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-3-319-33198-0_8openalex-snapshot
Prognostic Scores for Patients with Chronic Myeloid Leukemia Under Particular Consideration of Disease-Specific Death
inferred← citeshttps://doi.org/10.1007/978-3-319-33198-0_9openalex-snapshot
Response-Related Predictors of Survival in CML
inferred← citeshttps://doi.org/10.1007/978-3-319-39708-5_8openalex-snapshot
Targeted Therapy and Precision Medicine
inferred← citeshttps://doi.org/10.1007/978-3-319-48683-3_27openalex-snapshot
Future of Drug Discovery
inferred← citeshttps://doi.org/10.1007/978-3-319-64263-5_1openalex-snapshot
A History of the Chronic Leukemias
inferred← citeshttps://doi.org/10.1007/978-3-319-64263-5_5openalex-snapshot
Diagnosis and Treatment of Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-3-319-71553-7_2openalex-snapshot
Tyrosine Kinases, microRNAs, Epigenetics: New Insights in the Mechanisms of Leukemogenesis
inferred← citeshttps://doi.org/10.1007/978-3-319-74588-6_93openalex-snapshot
Blast Crisis of Chronic Myeloid Leukemia (CML)
inferred← citeshttps://doi.org/10.1007/978-3-319-74698-2_93-1openalex-snapshot
Blast Crisis of Chronic Myeloid Leukemia (CML)
inferred← citeshttps://doi.org/10.1007/978-3-319-74698-2_93-2openalex-snapshot
Blast Phase of Chronic Myeloid Leukemia (CML)
inferred← citeshttps://doi.org/10.1007/978-3-319-91439-8_5openalex-snapshot
Ponatinib: A Third-Generation Inhibitor for the Treatment of CML
inferred← citeshttps://doi.org/10.1007/978-3-319-93402-0_9openalex-snapshot
Peripheral Artery Disease and Stroke
inferred← citeshttps://doi.org/10.1007/978-3-319-97873-4_35openalex-snapshot
Neoplastic Hematologic Disorders in Children and Adolescents
inferred← citeshttps://doi.org/10.1007/978-3-642-54490-3_5openalex-snapshot
Ponatinib: A Third-Generation Inhibitor for the Treatment of CML
inferred← citeshttps://doi.org/10.1007/978-3-642-54676-1_464-2openalex-snapshot
Chronische myeloische Leukämie
inferred← citeshttps://doi.org/10.1007/978-3-662-46764-0_369-1openalex-snapshot
Substanzen gegen molekulare Zielstrukturen
inferred← citeshttps://doi.org/10.1007/978-4-431-55714-2_4openalex-snapshot
Goals of CML Treatment in the Tyrosine Kinase Inhibitor Era
inferred← citeshttps://doi.org/10.1007/978-4-431-55714-2_5openalex-snapshot
Biomarkers for Determining the Prognosis of CML
inferred← citeshttps://doi.org/10.1007/978-4-431-55714-2_6openalex-snapshot
Updated European LeukemiaNet Recommendations for the Management of CML
inferred← citeshttps://doi.org/10.1007/978-4-431-55714-2_8openalex-snapshot
Recommendations for the Management of CML in the Era of Second-Generation TKIs
inferred← citeshttps://doi.org/10.1007/978-94-007-4798-2_29openalex-snapshot
ABL-Kinase Mutations in Progenitors and Stem Cells from Chronic Myeloid Leukemia Patients
inferred← citeshttps://doi.org/10.1007/978-94-007-5028-9_13openalex-snapshot
Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-94-007-5028-9_14openalex-snapshot
Novel Targeted Therapeutics for Acute Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/978-981-10-3332-2_4openalex-snapshot
Dasatinib, Nilotinib, Bosutinib, Ponatinib, and Other TKIs
inferred← citeshttps://doi.org/10.1007/978-981-99-3810-0_48openalex-snapshot
Current Guidelines and Treatment Algorithm of Chronic Myeloid Leukemia
inferred← citeshttps://doi.org/10.1007/s00044-022-03011-9openalex-snapshot
Asciminib: first FDA approved allosteric inhibitor of BCR-ABL1 for the treatment of chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1007/s00108-010-2782-3openalex-snapshot
Moderne Therapie der chronisch myeloischen Leukämie
inferred← citeshttps://doi.org/10.1007/s00108-011-2818-3openalex-snapshot
Thyrosinkinaseinhibitoren in der Onkologie
inferred← citeshttps://doi.org/10.1007/s00108-011-2895-3openalex-snapshot
Neue Tyrosinkinase- und EGFR-Inhibitoren in der Tumortherapie
inferred← citeshttps://doi.org/10.1007/s00108-012-3152-0openalex-snapshot
Maßgeschneiderte Therapie der chronischen myeloischen Leukämie
inferred← citeshttps://doi.org/10.1007/s00204-014-1385-5openalex-snapshot
Combination therapy with nilotinib for drug-sensitive and drug-resistant BCR-ABL-positive leukemia and other malignancies
inferred← citeshttps://doi.org/10.1007/s00228-011-1200-7openalex-snapshot
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase
inferred← citeshttps://doi.org/10.1007/s00228-015-1968-yopenalex-snapshot
Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia
inferred← citeshttps://doi.org/10.1007/s00262-011-1096-1openalex-snapshot
The immune inhibitory receptor osteoactivin is upregulated in monocyte-derived dendritic cells by BCR–ABL tyrosine kinase inhibitors
inferred← citeshttps://doi.org/10.1007/s00262-018-2129-9openalex-snapshot
The BCR-ABL inhibitor nilotinib influences phenotype and function of monocyte-derived human dendritic cells
inferred← citeshttps://doi.org/10.1007/s00277-012-1458-6openalex-snapshot
Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals?
showing the first 200 of 1622 · page through all 1622
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.